<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492763</url>
  </required_header>
  <id_info>
    <org_study_id>8521-004</org_study_id>
    <secondary_id>MK-8521-004</secondary_id>
    <nct_id>NCT02492763</nct_id>
  </id_info>
  <brief_title>A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)</brief_title>
  <official_title>A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter randomized, double-blind, placebo- and active-controlled (liraglutide;
      Victoza®), parallel-group, clinical trial of MK-8521 in participants with type 2 diabetes
      mellitus (T2DM) with inadequate glycemic control while on a stable dose of metformin (≥1000
      mg/day).

      The trial will include a 1-week screening period; at least an 8-week antihyperglycemic agent
      (AHA) washout period, if required; a 14-week blinded therapy period (which includes
      single-blind run-in and double-blind therapy); and a 14-day post-treatment visit, 2 weeks
      after the last dose of investigational product.

      The primary hypothesis of the trial is that MK-8521 provides greater reduction in hemoglobin
      A1C relative to placebo after 12 weeks of once-daily administration in participants with T2DM
      with inadequate glycemic control on metformin monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">July 27, 2015</start_date>
  <completion_date type="Actual">April 18, 2017</completion_date>
  <primary_completion_date type="Actual">April 18, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1C (A1C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>A1C is the percentage of hemoglobin that has glucose bound to it and is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is reported as a percentage (%). This change from baseline reflects the Week 12 A1C minus the Week 0 A1C.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Adverse Event (AE)</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to an AE</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an AE of Symptomatic Hypoglycemia</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Hypoglycemia episodes are those with glucose values ≤70 mg/dL (3.9 mmol/L). Symptomatic hypoglycemia episodes were episodes with clinical symptoms reported by the investigator as hypoglycemia and classified as adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Heart Rate at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>This change from baseline reflects the Week 12 heart rate minus the Week 0 heart rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>This change from baseline reflects the Week 12 body weight minus the Week 0 body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>This change from baseline reflects the Week 12 FPG minus the Week 0 FPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Low Density Lipoprotein (LDL) Cholesterol at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>This change from baseline reflects the Week 12 fasting LDL cholesterol minus the Week 0 fasting LDL cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting High Density Lipoprotein (HDL) Cholesterol at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>This change from baseline reflects the Week 12 fasting HDL cholesterol minus the Week 0 fasting HDL cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Triglycerides at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>This change from baseline reflects the Week 12 fasting triglycerides minus the Week 0 fasting triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>This change from baseline reflects the Week 12 SBP minus the Week 0 SBP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>This change from baseline reflects the Week 12 DBP minus the Week 0 DBP.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>MK-8521 300 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive double-blind MK-8521 300 μg daily (QD), subcutaneously, over 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8521 180 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive double-blind MK-8521 180 μg QD, subcutaneously, over 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive matching double-blind placebo, QD over 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 1.8 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive open-label 1.8 mg of liraglutide, QD, subcutaneously, over 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8521</intervention_name>
    <description>Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen [60 μg, 120 μg] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen [60 μg, 120 μg, 180 μg] over the first 3 weeks is used to achieve the final dose up to 300 μg.</description>
    <arm_group_label>MK-8521 300 μg</arm_group_label>
    <arm_group_label>MK-8521 180 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.</description>
    <arm_group_label>MK-8521 300 μg</arm_group_label>
    <arm_group_label>MK-8521 180 μg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Dose strength: 1.8 mg QD administered subcutaneously. A 2-step dose escalation regimen (0.6 mg, 1.2 mg) over the first 2 weeks is used to achieve the final dose up to 1.8 mg.</description>
    <arm_group_label>Liraglutide 1.8 mg</arm_group_label>
    <other_name>Victoza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy</description>
    <arm_group_label>MK-8521 300 μg</arm_group_label>
    <arm_group_label>MK-8521 180 μg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Liraglutide 1.8 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have T2DM in accordance with American Diabetes Association guidelines

          -  Be on metformin monotherapy (&gt;-1000 mg/day: metformin IR or metformin XR) for at least
             12 weeks prior to study start with a hemoglobin A1C (A1C) &gt;-7.5 and &lt;-10.5% OR Be on
             dual therapy with metformin (&gt;-1000 mg/day: dose stable for at least 4 weeks prior to
             study start) with an A1C of &gt;-7.0% and &lt;-10.0% and a second AHA and be willing to
             washout the second AHA. Allowable AHAs are dipeptidyl peptidase 4 (DPP-4 inhibitors),
             alpha-glucosidase inhibitors, sulfonylureas, and glinides.

          -  Have a body mass index (BMI) ≥23 kg/m^2 and ≤40 kg/m^2

          -  Is a female who is not of reproductive potential, or is a female of reproductive
             potential who agrees to avoid becoming pregnant: while receiving study drug and for 14
             days after the last dose of study drug

        Exclusion Criteria:

          -  Have a history of type 1 diabetes or a history of diabetic ketoacidosis

          -  Has a history of other specific types of diabetes (e.g., genetic syndromes, secondary
             pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and
             post-organ transplant)

          -  Has been treated with any gut-derived incretin hormone glucagon-like peptide 1 (GLP-1)
             receptor agonist (e.g. Byetta™, Victoza™ or investigational agents) within the last 6
             months or has had GLP-1 receptor agonist discontinued due to gastrointestinal
             intolerance or lack of efficacy. Note: treatment with a GLP-1 receptor agonist that
             was discontinued &gt;6 months prior to study start is not an exclusion if the GLP-1
             receptor agonist was discontinued for reasons other than gastrointestinal intolerance
             or lack of efficacy.

          -  Has a history of clinically significant gastrointestinal disorder (including diabetic
             gastroparesis; irritable bowel disease; recurrent episodes of nausea, vomiting,
             diarrhea and abdominal pain)

          -  Has a history of clinically significant and active, immunological, respiratory,
             genitourinary or major neurological (including stroke, transient ischemic attack and
             chronic seizures) abnormalities or diseases

          -  Has a history of cardiovascular disease (including diabetic cardiomyopathy) or
             significant cardiac condition (including a history of myocardial infarction, stable or
             unstable angina, arterial revascularization, pathologic, symptomatic or sustained
             tachyarrhythmia [e.g. atrial fibrillation, sustained supraventricular tachycardia,
             symptomatic non-sustained supraventricular tachycardia, ventricular tachycardia,
             ventricular fibrillation, Wolf-Parkinson-White syndrome, congenital long QT syndrome,
             etc.]) or heart failure

          -  Has a family history of medullary carcinoma of the thyroid or multiple endocrine
             neoplasm type-2 syndrome

          -  Has active diabetic proliferative retinopathy or a history of maculopathy

          -  Has human immunodeficiency virus (HIV)

          -  Has a medical history of active liver disease (other than non-alcoholic hepatic
             steatosis), including chronic hepatitis B or C (assessed by medical history), primary
             biliary cirrhosis, or active symptomatic gallbladder disease

          -  Is on a weight loss medication or has undergone bariatric surgery

          -  Has a history of acute or chronic pancreatitis of any etiology

          -  Had an event of severe hypoglycemia with neuroglycopenia in the past 12 months

          -  Has a positive urine pregnancy test

          -  Is pregnant or breast-feeding, or is planning to conceive during the trial, including
             14 days following the last dose of investigational product

          -  Routinely consumes &gt;1 alcoholic drinks per day or &gt;7 alcoholic drinks per week or
             engages in binge drinking

          -  Routinely consumes ≥480mg /day caffeine in caffeinated beverages (1 cup of coffee
             contains approximately 120 mg of caffeine

          -  Is taking a beta blocker or medications with sympathomimetic activity (e.g.
             pseudoephedrine, phenylpropanolamine, etc.)

          -  Is currently a user of nicotine or nicotine containing products or does not agree to
             refrain from using nicotine during the trial, including 14 days following the last
             dose of investigational product

          -  Is currently a user of any illicit drugs (including any marijuana use) or has a
             history of drug (including alcohol) abuse within approximately 5 years

          -  has other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or blinded
             investigational product administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Colombia</country>
    <country>Guatemala</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <results_first_submitted>January 18, 2018</results_first_submitted>
  <results_first_submitted_qc>February 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 8, 2018</results_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 84 clinical trial sites in Australia, Colombia, Guatemala, Israel, Spain, New Zealand, and in the United States. Five hundred participants were screened and 176 randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MK-8521 180 μg</title>
          <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>MK-8521 300 μg</title>
          <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Liraglutide 1.8 mg</title>
          <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hyperglycemia Discontinuation Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants randomized</population>
      <group_list>
        <group group_id="B1">
          <title>MK-8521 180 μg</title>
          <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>MK-8521 300 μg</title>
          <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Liraglutide 1.8 mg</title>
          <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="43"/>
            <count group_id="B5" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="7.6"/>
                    <measurement group_id="B2" value="54.2" spread="7.9"/>
                    <measurement group_id="B3" value="51.5" spread="10.1"/>
                    <measurement group_id="B4" value="52.9" spread="9.4"/>
                    <measurement group_id="B5" value="53.2" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C Classification by Levels</title>
          <description>Hemoglobin A1C classification by levels: &lt;8.5% or &gt;=8.5%</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;8.5%</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=8.5%</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antihyperglycemic agent (AHA) Washout Status</title>
          <description>AHA washout status (yes/no). The trial included an 8-week AHA washout period for participants taking a AHA.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Number of participants with a BMI &lt;30 kg/m^2 or BMI&gt;=30 kg/m^2</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;30 kg/m^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 kg/m^2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Rate</title>
          <population>All randomized participants who had a baseline heart rate value.</population>
          <units>Beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="42"/>
                    <count group_id="B5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" spread="7.7"/>
                    <measurement group_id="B2" value="72.2" spread="9.9"/>
                    <measurement group_id="B3" value="73.8" spread="8.6"/>
                    <measurement group_id="B4" value="74.7" spread="8.9"/>
                    <measurement group_id="B5" value="73.3" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.4" spread="41.0"/>
                    <measurement group_id="B2" value="175.0" spread="49.5"/>
                    <measurement group_id="B3" value="172.0" spread="39.2"/>
                    <measurement group_id="B4" value="187.5" spread="44.9"/>
                    <measurement group_id="B5" value="176.4" spread="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Low Density Lipoprotein (LDL) Cholesterol</title>
          <population>All randomized participants who had a baseline fasting LDL cholesterol value.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="40"/>
                    <count group_id="B5" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103.3" spread="28.1"/>
                    <measurement group_id="B2" value="95.6" spread="33.8"/>
                    <measurement group_id="B3" value="100.5" spread="42.8"/>
                    <measurement group_id="B4" value="93.0" spread="29.5"/>
                    <measurement group_id="B5" value="98.2" spread="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting High Density Lipoprotein (HDL) Cholesterol</title>
          <population>All randomized participants who had a baseline fasting HDL cholesterol value.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="40"/>
                    <count group_id="B5" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.4" spread="12.3"/>
                    <measurement group_id="B2" value="41.7" spread="9.5"/>
                    <measurement group_id="B3" value="43.1" spread="12.0"/>
                    <measurement group_id="B4" value="46.8" spread="13.8"/>
                    <measurement group_id="B5" value="44.8" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Triglycerides</title>
          <population>All randomized participants who had a baseline fasting triglycerides value.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="42"/>
                    <count group_id="B5" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.5" spread="104.6"/>
                    <measurement group_id="B2" value="167.1" spread="79.5"/>
                    <measurement group_id="B3" value="168.7" spread="96.1"/>
                    <measurement group_id="B4" value="154.0" spread="89.5"/>
                    <measurement group_id="B5" value="165.5" spread="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure (SBP)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125.1" spread="10.8"/>
                    <measurement group_id="B2" value="126.0" spread="12.0"/>
                    <measurement group_id="B3" value="124.6" spread="14.3"/>
                    <measurement group_id="B4" value="126.3" spread="11.0"/>
                    <measurement group_id="B5" value="125.5" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure (DBP)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.6" spread="6.3"/>
                    <measurement group_id="B2" value="77.9" spread="7.4"/>
                    <measurement group_id="B3" value="77.6" spread="8.3"/>
                    <measurement group_id="B4" value="78.9" spread="5.7"/>
                    <measurement group_id="B5" value="77.7" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.54" spread="0.82"/>
                    <measurement group_id="B2" value="8.43" spread="0.78"/>
                    <measurement group_id="B3" value="8.46" spread="0.83"/>
                    <measurement group_id="B4" value="8.72" spread="1.03"/>
                    <measurement group_id="B5" value="8.54" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="44"/>
                    <count group_id="B3" value="43"/>
                    <count group_id="B4" value="43"/>
                    <count group_id="B5" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.4" spread="18.1"/>
                    <measurement group_id="B2" value="89.4" spread="20.0"/>
                    <measurement group_id="B3" value="90.2" spread="19.0"/>
                    <measurement group_id="B4" value="92.4" spread="16.5"/>
                    <measurement group_id="B5" value="89.3" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 12</title>
        <description>A1C is the percentage of hemoglobin that has glucose bound to it and is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is reported as a percentage (%). This change from baseline reflects the Week 12 A1C minus the Week 0 A1C.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized, treated participants with at least one A1C measurement (baseline or post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 12</title>
          <description>A1C is the percentage of hemoglobin that has glucose bound to it and is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is reported as a percentage (%). This change from baseline reflects the Week 12 A1C minus the Week 0 A1C.</description>
          <population>All randomized, treated participants with at least one A1C measurement (baseline or post-baseline).</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" lower_limit="-1.16" upper_limit="-0.49"/>
                    <measurement group_id="O2" value="-1.05" lower_limit="-1.41" upper_limit="-0.69"/>
                    <measurement group_id="O3" value="-0.44" lower_limit="-0.80" upper_limit="-0.08"/>
                    <measurement group_id="O4" value="-1.42" lower_limit="-1.77" upper_limit="-1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.126</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.146</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</p_value_desc>
            <method>Longitudinal data analysis</method>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Adverse Event (AE)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to Week 14</time_frame>
        <population>All randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Adverse Event (AE)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>All randomized participants who received at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Treatment Due to an AE</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>All randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Treatment Due to an AE</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>All randomized participants who received at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an AE of Symptomatic Hypoglycemia</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Hypoglycemia episodes are those with glucose values ≤70 mg/dL (3.9 mmol/L). Symptomatic hypoglycemia episodes were episodes with clinical symptoms reported by the investigator as hypoglycemia and classified as adverse events.</description>
        <time_frame>Up to Week 14</time_frame>
        <population>All randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an AE of Symptomatic Hypoglycemia</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Hypoglycemia episodes are those with glucose values ≤70 mg/dL (3.9 mmol/L). Symptomatic hypoglycemia episodes were episodes with clinical symptoms reported by the investigator as hypoglycemia and classified as adverse events.</description>
          <population>All randomized participants who received at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.301</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.573</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>13.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.295</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in % vs Liraglutide</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.4</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.587</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in % vs Liraglutide</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>13.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Heart Rate at Week 12</title>
        <description>This change from baseline reflects the Week 12 heart rate minus the Week 0 heart rate.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized, treated participants with at least one heart rate measurement (baseline or post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate at Week 12</title>
          <description>This change from baseline reflects the Week 12 heart rate minus the Week 0 heart rate.</description>
          <population>All randomized, treated participants with at least one heart rate measurement (baseline or post-baseline).</population>
          <units>Beats/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.47" lower_limit="2.99" upper_limit="7.96"/>
                    <measurement group_id="O2" value="6.28" lower_limit="3.72" upper_limit="8.84"/>
                    <measurement group_id="O3" value="-1.42" lower_limit="-3.92" upper_limit="1.07"/>
                    <measurement group_id="O4" value="1.63" lower_limit="-0.88" upper_limit="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in the LS Means vs. Placebo</param_type>
            <param_value>6.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.42</ci_lower_limit>
            <ci_upper_limit>10.37</ci_upper_limit>
            <estimate_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</estimate_desc>
            <other_analysis_desc>Longitudinal data analysis</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in LS Means vs. Liraglutide</param_type>
            <param_value>3.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>7.33</ci_upper_limit>
            <estimate_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</estimate_desc>
            <other_analysis_desc>Longitudinal data analysis</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in LS Means vs. Placebo</param_type>
            <param_value>7.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.17</ci_lower_limit>
            <ci_upper_limit>11.23</ci_upper_limit>
            <estimate_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</estimate_desc>
            <other_analysis_desc>Longitudinal data analysis</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in LS Means vs. Liraglutide</param_type>
            <param_value>4.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>8.19</ci_upper_limit>
            <estimate_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</estimate_desc>
            <other_analysis_desc>Longitudinal data analysis</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 12</title>
        <description>This change from baseline reflects the Week 12 body weight minus the Week 0 body weight.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized, treated participants with at least one body weight measurement (baseline or post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 12</title>
          <description>This change from baseline reflects the Week 12 body weight minus the Week 0 body weight.</description>
          <population>All randomized, treated participants with at least one body weight measurement (baseline or post-baseline).</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-2.9" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-4.0" upper_limit="-2.1"/>
                    <measurement group_id="O3" value="-1.3" lower_limit="-2.2" upper_limit="-0.3"/>
                    <measurement group_id="O4" value="-2.9" lower_limit="-3.8" upper_limit="-1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.285</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.183</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.811</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</p_value_desc>
            <method>Longitudinal data analysis</method>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</title>
        <description>This change from baseline reflects the Week 12 FPG minus the Week 0 FPG.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized, treated participants with at least one FPG measurement (baseline or post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</title>
          <description>This change from baseline reflects the Week 12 FPG minus the Week 0 FPG.</description>
          <population>All randomized, treated participants with at least one FPG measurement (baseline or post-baseline).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" lower_limit="-27.7" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-34.6" lower_limit="-49.3" upper_limit="-19.9"/>
                    <measurement group_id="O3" value="-5.1" lower_limit="-19.4" upper_limit="9.2"/>
                    <measurement group_id="O4" value="-42.9" lower_limit="-57.0" upper_limit="-28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.385</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.2</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>29.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.7</ci_lower_limit>
            <ci_upper_limit>48.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-29.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.6</ci_lower_limit>
            <ci_upper_limit>-9.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.416</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>8.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7</ci_lower_limit>
            <ci_upper_limit>28.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</p_value_desc>
            <method>Longitudinal data analysis</method>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-37.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.5</ci_lower_limit>
            <ci_upper_limit>-18.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Low Density Lipoprotein (LDL) Cholesterol at Week 12</title>
        <description>This change from baseline reflects the Week 12 fasting LDL cholesterol minus the Week 0 fasting LDL cholesterol.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized, treated participants with at least one fasting LDL cholesterol measurement (baseline or post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Low Density Lipoprotein (LDL) Cholesterol at Week 12</title>
          <description>This change from baseline reflects the Week 12 fasting LDL cholesterol minus the Week 0 fasting LDL cholesterol.</description>
          <population>All randomized, treated participants with at least one fasting LDL cholesterol measurement (baseline or post-baseline).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="23.5"/>
                    <measurement group_id="O2" value="8.8" spread="41.8"/>
                    <measurement group_id="O3" value="4.5" spread="33.5"/>
                    <measurement group_id="O4" value="0.3" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting High Density Lipoprotein (HDL) Cholesterol at Week 12</title>
        <description>This change from baseline reflects the Week 12 fasting HDL cholesterol minus the Week 0 fasting HDL cholesterol.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized, treated participants with at least one fasting HDL cholesterol measurement (baseline or post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting High Density Lipoprotein (HDL) Cholesterol at Week 12</title>
          <description>This change from baseline reflects the Week 12 fasting HDL cholesterol minus the Week 0 fasting HDL cholesterol.</description>
          <population>All randomized, treated participants with at least one fasting HDL cholesterol measurement (baseline or post-baseline).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="12.3"/>
                    <measurement group_id="O2" value="-0.5" spread="6.0"/>
                    <measurement group_id="O3" value="3.8" spread="6.6"/>
                    <measurement group_id="O4" value="0.4" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Triglycerides at Week 12</title>
        <description>This change from baseline reflects the Week 12 fasting triglycerides minus the Week 0 fasting triglycerides.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized, treated participants with at least one fasting triglycerides measurement (baseline or post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Triglycerides at Week 12</title>
          <description>This change from baseline reflects the Week 12 fasting triglycerides minus the Week 0 fasting triglycerides.</description>
          <population>All randomized, treated participants with at least one fasting triglycerides measurement (baseline or post-baseline).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="91.9"/>
                    <measurement group_id="O2" value="-26.6" spread="71.2"/>
                    <measurement group_id="O3" value="-15.6" spread="68.9"/>
                    <measurement group_id="O4" value="-20.5" spread="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) at Week 12</title>
        <description>This change from baseline reflects the Week 12 SBP minus the Week 0 SBP.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized, treated participants with at least one SBP measurement (baseline or post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) at Week 12</title>
          <description>This change from baseline reflects the Week 12 SBP minus the Week 0 SBP.</description>
          <population>All randomized, treated participants with at least one SBP measurement (baseline or post-baseline).</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" lower_limit="-6.4" upper_limit="0.9"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-5.2" upper_limit="2.3"/>
                    <measurement group_id="O3" value="1.0" lower_limit="-2.6" upper_limit="4.6"/>
                    <measurement group_id="O4" value="-1.7" lower_limit="-5.3" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.682</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.344</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.948</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.306</p_value>
            <p_value_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</p_value_desc>
            <method>Longitudinal data analysis</method>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.8</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12</title>
        <description>This change from baseline reflects the Week 12 DBP minus the Week 0 DBP.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized, treated participants with at least one DBP measurement (baseline or post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8521 180 μg</title>
            <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MK-8521 300 μg</title>
            <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Liraglutide 1.8 mg</title>
            <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12</title>
          <description>This change from baseline reflects the Week 12 DBP minus the Week 0 DBP.</description>
          <population>All randomized, treated participants with at least one DBP measurement (baseline or post-baseline).</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-1.7" upper_limit="2.8"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-1.9" upper_limit="2.8"/>
                    <measurement group_id="O3" value="-1.0" lower_limit="-3.3" upper_limit="1.3"/>
                    <measurement group_id="O4" value="0.6" lower_limit="-1.7" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.347</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.963</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.394</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.905</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.325</p_value>
            <method>Longitudinal data analysis</method>
            <method_desc>Terms for treatment, time, A1C (&lt;8.5%, ≥8.5%), BMI (&lt;30 kg/m^2, ≥30 kg/m^2) and AHA washout status (Yes, No), and the interaction of time by treatment</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 14</time_frame>
      <desc>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The analysis population included all treated participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-8521 180 μg</title>
          <description>Participants receive double-blind MK-8521 180 μg daily (QD), subcutaneously, over 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>MK-8521 300 μg</title>
          <description>Participants receive double-blind MK-8521 300 μg, QD, subcutaneously, over 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants receive matching double-blind placebo QD over 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Liraglutide 1.8 mg</title>
          <description>Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

